Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 18 through 49 years and in good health by history, physical exam, and labs~* Weight greater than or equal to (\>=) 45 kilogram (kg) and less than or equal to (\<=) 110 kg at Screening~* Written informed consent prior to performing any protocol related procedures, including Screening evaluations~* Ability to complete the Follow-up period of 360 days~Key Exclusion Criteria:~* Acute illness including fever \>= 99.5 Fahrenheit (°F) on day of dosing~* Any drug therapy within 7 days prior to Day 1 (except contraceptives)~* Receipt of any investigational drug therapy within 120 days prior to investigational product dosing through 360 days after investigational product dosing~* Previous receipt of a monoclonal antibody (mAb)~* Pregnant or nursing mother~* Concurrent enrollment in another interventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- MEDI8897 300 milligram (mg) Intravenous (IV) (Type: EXPERIMENTAL): Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
- MEDI8897 1000 mg IV (Type: EXPERIMENTAL): Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
- MEDI8897 3000 mg IV (Type: EXPERIMENTAL): Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
- MEDI8897 100 mg Intramuscular (IM) (Type: EXPERIMENTAL): Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
- MEDI8897 300 mg IM (Type: EXPERIMENTAL): Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).